Treatment Approach and Outcomes in Infants with Localized Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
IJROBP Journal SA-CME activity for January 1, 2019 (Volume 103, Issue 1) is designed to help predict potential outcomes for infants that do not receive standard radiotherapy per protocol.
Substantial concern exists for using local radiotherapy for children < 24 months old due to the risk of late effects from this therapy. In order to improve enrollment, the ARST0331 and ARST0531 allowed individualization of therapy for these patients enrolled on the trial and in many cases radiotherapy was omitted or delayed. The value of radiotherapy may not be well known for this group of patients particularly in light of a complete response to chemotherapy. This report and this CME activity seek to highlight any differences in outcome with individualized therapy for these patients to guide the participant’s practice.
Please click here to read the related journal article online.
This activity is available from January 11, 2019, through 11:59 p.m. Eastern time on January 10, 2021.
This program is designed to meet the interest of radiation oncologists, radiation oncology residents and nurses.
- Predict potential outcomes for children<24 months of age that do not receive standard radiotherapy per protocol.
- Distinguish between differences in local relapse and event free and overall survival outcomes in children with Rhabdomyosarcoma.
Brandi Page, MD has no financial relationships with a commercial interest.
Anthony Zietman, MD, FASTRO is employed by Massachusetts General Hospital and Elsevier, receives compensation/remuneration/funding from the National Cancer Institute (NCI) and holds leadership positions at ABR and NCI.
Julie Bradley receives compensation/remuneration/funding from Ion Beam Applications, Children's Oncology Group, NCI, and NIH.
The person(s) above served as the developer(s) of this activity. Additionally, the Journal CME Task Force and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $30
- Member: $25
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.